MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet clinical trials

SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

This study looks at a new drug, ODM-208, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It checks if the drug is safe, what dose works best, and how it moves through the body.